Boceprevir and Telaprevir Near FDA Approval: Will Quickly Change HCV Development Rules

The upcoming launch of two new hepatitis C therapies will be one of the biggest biopharmaceutical stories of 2011. But FDA’s antiviral regulatory group is keen to make sure that is only the first chapter in a long story of advances in treatment in the class.